Patents Assigned to Eisai R&D Management Co., Ltd.
  • Liposome composition
    Patent number: 11071713
    Abstract: The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: July 27, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Hiroshi Kikuchi, Kenji Hyodo, Hiroshi Ishihara
  • Methods for the Treatment of Bladder Cancer
    Publication number: 20210205348
    Abstract: Provided herein are methods for the treatment of bladder cancer.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 8, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Method and pharmaceutical composition for treating Crohn's disease
    Patent number: 11052150
    Abstract: It is an object of the present invention to provide a pharmaceutical composition comprising an anti-fractalkine antibody that provides therapeutically effective improvement to Crohn's disease, after the administration thereof to a human subject, and a method for treating Crohn's disease. Provided is a pharmaceutical composition for treating Crohn's disease. The present pharmaceutical composition comprises an anti-fractalkine antibody and a pharmaceutically acceptable excipient, and is used, such that the anti-fractalkine antibody is intravenously administered to a human at a dose of at least 10 mg/kg of human body weight in a method for treating Crohn's disease.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: July 6, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Nobuyuki Yasuda, Kiyoshi Oketani, Hiroko Baba, Tomohisa Nakano, Masahiko Mori
  • SALTS OF COMPOUNDS AND CRYSTALS THEREOF
    Publication number: 20210198282
    Abstract: The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38, 40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34?5,39?5-diphosphaoctacyclo[28.6.4.13,36.128,31.04,8.07,12.019,24.023,27]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals.
    Type: Application
    Filed: August 14, 2019
    Publication date: July 1, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Jun NIIJIMA, Hirofumi KURODA, So YASUI, Yoko ITO, Ikuo KUSHIDA
  • MACROCYCLIZATION REACTIONS AND INTERMEDIATES AND OTHER FRAGMENTS USEFUL IN THE SYNTHESIS OF ANALOGS OF HALICHONDRIN B
    Publication number: 20210188867
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Applicants: EISAI R&D MANAGEMENT CO., LTD., EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE, Jaemoon LEE
  • CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20210177837
    Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy.
    Type: Application
    Filed: April 11, 2019
    Publication date: June 17, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Andrew COOK, Dominic REYNOLDS, Cheng ZHONG, Ryan BRAWN, Shelby ELLERY, Thiwanka SAMARAKOON, Xiang LIU, Sudeep PRAJAPATI, Megan SHEEHAN, Jason T. LOWE, James PALACINO
  • PHARMACEUTICAL COMPOSITION FOR TREATING TUMOR
    Publication number: 20210177802
    Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 17, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi
  • Anti-EphA4 antibody
    Patent number: 11034769
    Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: June 15, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Eiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani
  • CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS
    Publication number: 20210171555
    Abstract: We provide diastereomerically pure or substantially diastereomerically pure activated phosphoramidochloridate morpholino nucleosides, methods of their preparation, and methods of their use in stereospecific coupling for stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs).
    Type: Application
    Filed: October 28, 2020
    Publication date: June 10, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi ENDO, Robert T. YU, Francis FANG, Hyeong Wook CHOI, Mingde SHAN
  • Anti-EphA4 Antibody
    Publication number: 20210171644
    Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
    Type: Application
    Filed: January 8, 2021
    Publication date: June 10, 2021
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Eiji INOUE, Akio YAMADA, Tomomi KAWAKATSU, Toshio IMAI, Maki DEGUCHI, Aki NAKATANI
  • Compositions and methods for treating insomnia
    Patent number: 11026944
    Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: June 8, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Margaret Moline, Gina Pastino, Yurie Akimoto, Yasuhiro Zaima, Nobuya Suzuki, Nobuo Yoshida
  • CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20210163456
    Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 3, 2021
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. KEANEY, John WANG, Baudouin GERARD, Kenzo ARAI, Xiang LIU, Guo Zhu ZHENG, Kazunobu KIRA, Lisa A. MARCAURELLE, Marta NEVALAINEN, Ming-Hong HAO, Morgan Welzel O'SHEA, Parcharee TIVITMAHAISOON, Sudeep PRAJAPATI, Touping LUO, Nicholas C. GEARHART, Jason T. LOWE, Yoshihiko KOTAKE, Satoshi NAGAO, Regina Mikie KANADA SONOBE, Masayuki MIYANO, Norio MURAI, Andrew COOK, Shelby ELLERY, Atsushi ENDO, James PALACINO, Dominic REYNOLDS
  • BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND A PD-1 ANTAGONIST
    Publication number: 20210123919
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a combination therapy comprising lenvatinib compound and a PD-1 antagonist. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing cancer.
    Type: Application
    Filed: May 13, 2019
    Publication date: April 29, 2021
    Applicants: Merck Sharp & Dohme Corp., Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro FUNAHASHI, Kotaro KODAMA, Ryo DAIRIKI, Yukinori MINOSHIMA
  • COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20210113537
    Abstract: Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.
    Type: Application
    Filed: March 16, 2018
    Publication date: April 22, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Craig D. KARR, Manav KORPAL, Nathalie RIOUX, Peter Gerard SMITH
  • Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
    Patent number: 10981929
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides or analogs thereof through a cyclization reaction strategy. The strategy of the present invention involves subjecting an intermediate to Prins reaction conditions to afford a macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides or analogs thereof and methods for preparing the same.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 20, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Hyeong-Wook Choi, Atsushi Endo, Francis G. Fang, Dae-Shik Kim
  • SALT OF PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND AND CRYSTALS THEREOF
    Publication number: 20210107907
    Abstract: A salt of the compound represented by formula (1) and crystals thereof having the potential to be used as drug substances for pharmaceutical products.
    Type: Application
    Filed: February 22, 2019
    Publication date: April 15, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventor: Taro YAMASHITA
  • Macrocyclic compound and uses thereof
    Patent number: 10954249
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 23, 2021
    Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., Ltd.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Combination of a PD-1 antagonist and eribulin for treating cancer
    Patent number: 10945990
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 16, 2021
    Assignees: EISAI R&D MANAGEMENT CO., LTD., MERCK SHARP & DOHME CORP.
    Inventors: Junji Matsui, Gursel Aktan, Vassiliki Karantza, RuiRong Yuan, Yasuhiro Funahashi, Erhan Berrak
  • Cationic lipid
    Patent number: 10947193
    Abstract: The present invention provides a cationic lipid which is able to be used for nucleic acid delivery to the cytoplasm. A cationic lipid according to the present invention is, for example, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 independently represent an alkylene group having 3 to 10 carbon atoms; R1 and R2 independently represent an alkyl group having 4 to 24 carbon atoms or an alkenyl group having 4 to 24 carbon atoms; R3 represents an alkyl group having 1 to 3 carbon atoms; and X1 represents a single bond or CO—O—.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: March 16, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yuta Suzuki, Yoshinori Takahashi
  • Anti-EphA4 antibody
    Patent number: 10947313
    Abstract: Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: March 16, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Eiji Inoue, Akio Yamada, Tomomi Kawakatsu, Toshio Imai, Maki Deguchi, Aki Nakatani